Last Updated : May 1, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name Sort descending | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Votrient | Pazopanib hydrochloride | Metastatic Renal Cell Carcinoma | Reimburse | Complete | ||
| Votrient | Pazopanib Hydrochloride | Soft Tissue Sarcoma | Do not reimburse | Complete | ||
| Macugen | Pegaptanib sodium | Macular degeneration, age-related | Do not list | Complete | ||
| Oncaspar | Pegaspargase | CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer | Not filed | |||
| Empaveli | pegcetacoplan | Paroxysmal nocturnal hemoglobinuria | Reimburse with clinical criteria and/or conditions | Complete | ||
| TBC | pegcetacoplan | Geographic atrophy secondary to age-related macular degeneration | Pending | |||
| Lapelga | Pegfilgrastim | Febrile neutropenia | N/A | Complete | ||
| Fulphila | pegfilgrastim | Febrile neutropenia in non-myeloid malignancies | N/A | Complete | ||
| Neulasta | Pegfilgrastim | Neutropenia | List with clinical criteria and/or conditions | Complete | ||
| Pegasys RBV | Peginterferon alfa-2a and Ribavirin | Hepatitis C, chronic | List in a similar manner to other drugs in class | Complete |
Last Updated : May 1, 2024